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Abstract
Background: Treatment decision tools have been developed in many fields of medicine, including psychiatry,
however benefits for patients have not been sustained once the support is withdrawn. We have developed a
web-based computerised clinical decision support tool (CDST), which can provide patients and clinicians with
continuous, up-to-date, personalised information about the efficacy and tolerability of competing interventions. To test
the feasibility and acceptability of the CDST we conducted a focus group study, aimed to explore the views
of clinicians, patients and carers.
Methods: The CDST was developed in Oxford. To tailor treatments at an individual level, the CDST combines
the best available evidence from the scientific literature with patient preferences and values, and with patient
medical profile to generate personalised clinical recommendations. We conducted three focus groups comprising of
three different participant types: consultant psychiatrists, participants with a mental health diagnosis and/or experience
of caring for someone with a mental health diagnosis, and primary care practitioners and nurses. Each 1-h focus group
started with a short visual demonstration of the CDST. To standardise the discussion during the focus groups, we used
the same topic guide that covered themes relating to the acceptability and usability of the CDST. Focus groups were
recorded and any identifying participant details were anonymised. Data were analysed thematically and managed
using the Framework method and the constant comparative method.
Results: The focus groups took place in Oxford between October 2016 and January 2017. Overall 31 participants
attended (12 consultants, 11 primary care practitioners and 8 patients or carers). The main themes that emerged
related to CDST applications in clinical practice, communication, conflicting priorities, record keeping and data
management. CDST was considered a useful clinical decision support, with recognised value in promoting clinician-
patient collaboration and contributing to the development of personalised medicine. One major benefit of the CDST
was perceived to be the open discussion about the possible side-effects of medications. Participants from all the three
groups, however, universally commented that the terminology and language presented on the CDST were too
medicalised, potentially leading to ethical issues around consent to treatment.
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Conclusions: The CDST can improve communication pathways between patients, carers and clinicians, identifying care
priorities and providing an up-to-date platform for implementing evidence-based practice, with regard to
prescribing practices.
Keywords: Focus group, Treatment algorithm, Evidence based decision tool, Decision making
Background
The efficacy of current pharmacological and non-
pharmacological interventions in psychiatry is well estab-
lished and worthwhile, but still far from optimal [1].
Despite the enormous burden of psychiatric disorders
worldwide, progress in developing new treatments is
slow, in part due to inadequate knowledge of the bio-
psychosocial mechanisms underlying mental disorders
[2]. To improve clinical outcomes of patients it is
important to make use of all available scientific infor-
mation. Data from existing clinical studies are ideal
because they provide better estimates of comparative
efficacy between interventions, allowing treatment indica-
tions to be personalised, by stratifying results for specific
subgroups of patients according to baseline clinical and
demographic characteristics [3]. Through performing
sophisticated re-analyses of existing datasets, researchers
can predict the probability of a treatment response or
determine the chances that a person will have a particular
side effect [4]. By matching patients with treatments that
are more likely to be effective and cause fewer side effects,
clinicians can use this information to customize treat-
ments to patients’ needs, thus improving their out-
comes. This approach, known as “personalised” or
“precision medicine” is now widely used in many
fields of medicine [5].
To help clinicians adhere to evidence-based guidelines
and deliver standardized care based on the best-available
scientific information, medical algorithms have been
developed, such as in the treatment of hypertension, dia-
betes, high cholesterol, cancer and myocardial infarction.
Similarly, in psychiatry the Texas Medication Algorithm
Project developed an algorithm to assess its value in
managing the pharmacological treatment of patients
with schizophrenia, bipolar disorder and major depres-
sive disorder [6]. Even though clinical outcomes of
patients whose psychiatrists used this algorithm reported
a statistically significant benefit, studies have consistently
shown that the initial benefits of algorithm implementa-
tion are not sustained once the implementation support is
withdrawn [7].
Moreover, for the algorithm to truly become a clinical
tool, innovative methodologies are needed to support
probabilistic decision-making and incorporate patients’
views and clinical judgement in a dynamic way [8]. A dif-
ference in efficacy between interventions of 5%, for
instance, might mean more to one patient than to another
and it does not precisely exclude a benefit that clinicians
and patients might find meaningful. Or, vice versa, the
same result could allow some doctors and patients to
choose to avoid the treatment after careful consideration
of tolerability, risk and uncertainty.
For this reason, we have developed the prototype of a
new, cloud-based clinical decision support tool (CDST), a
treatment algorithm that aims at providing updated and
stratified information about interventions for different
subgroups of patients. To test the acceptability of the
CDST, we designed a focus group study that aimed to
explore clinicians’, patients’ and carers’ perspectives on the
algorithm prototype. In particular, we wanted to explore
whether participants felt it was a useful decision-making
tool for improving prescribing practices in routine
psychiatric care.
Methods
The CDST was developed by researchers at the University
of Oxford in collaboration with experts working at the
University of Tel Aviv (Fig. 1) and is part of a larger
research programme, which proposes to develop an inte-
grated system using remote technology to monitor clinical
outcomes using a machine learning approach. To tailor
treatments at an individual level, the CDST balances
stratified recommendations from network meta-analysis
(the best methodological design for comparative effective-
ness) [9] in combination with the preferences and values
of patients, carers and clinicians. To incorporate individ-
ual preferences, we used bar graphs reporting the percent-
age allocated to each side effects and the ranking of the
treatments based on the results from the network meta-
analysis. The final ranking of the best five interventions
will depend not only on the clinical and demographic
characteristics of the patient (information derived from
the randomised data) but also on the individual choice in
terms of tolerability profile (subjective preference). As a
working example for the CDST, we decided to use data
from randomised trials about efficacy and acceptability of
pharmacological treatments in schizophrenia [10]. How-
ever, the focus group discussion focused on the layout and
applicability of the CDST, rather than the clinical content
of the information provided.
We chose to use focus groups to investigate accept-
ability, to encourage participants to openly explore their
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own and others’ perspectives collectively, with opportun-
ity for clarification and debate, without using a rigid
framework. Three separate focus groups were planned:
one for consultant psychiatrists working in the National
Health Service (NHS) in the UK, one for patients and
carers, and one for general practitioners and nurses. We
conducted separate focus groups to allow participants to
speak freely without feeling inhibited in the presence of
other group members, thus facilitating discussion.
We checked with the local Ethics Committee and ethical
approvals were not required for the study, however writ-
ten informed consent was taken from each participant.
Access, recruitment and participant characteristics
The study took place in Oxford (United Kingdom)
between October 2016 and January 2017. We conducted
three focus groups comprising of three different partici-
pant types. The first was for Consultant Psychiatrists
working in the Oxford Health NHS Foundation Trust
each of which received an invitation and participant
information sheet via email. The second was for partici-
pants who had a prior mental health diagnosis and/or
experience of caring for someone with a mental health
diagnosis. They received a modified version of the partici-
pant information sheet in Plain English to ensure under-
standing. We managed to have a diverse representation of
mental health disorders, including schizophrenia, major
depression, bipolar disorder, anorexia and anxiety.
Participants for this group were initially identified
using a local Patient and the Public Involvement and
Engagement (PPI/E) group, followed by purposive sam-
pling to ensure diversity in age, gender, patient and carer
experience and technological abilities. The third focus
group comprised of primary care general practitioners and
nurses, following invitation to participate from a local gen-
eral practitioner (GP) practice.
Overall 31 participants attended the focus groups. Of
these 12 were consultant psychiatrists, 11 primary care
practitioners (general practitioners n = 6; nurses n = 5)
and eight were patients or carers. The majority of partic-
ipants were white British (n = 24, 77.4%), women
(n = 17, 54.8%) and aged over 45 years (n = 19, 61.3%)
(Table 1).
Both in the group of consultant psychiatrists and in
the group of general practitioners there were clinicians
who had been practicing for a long time (more than
20 years) as well as clinicians who were less experienced
(fewer than 10 years).
Each focus group lasted around one hour and started
with a short, interactive, visual demonstration of how the
CDST worked, before answering any questions relating to
the demonstration. To standardise the procedure, we used
the same topic guide that covered themes relating to the
acceptability and usability of the CDST (Table 2).
Data analysis
Focus groups were recorded using a digital voice recorder
before being transcribed by a local transcription service.
Any identifying participant details were anonymised and
Fig. 1 Layout of the clinical decision support tool (CDST). The CDST allows clinicians and patients to enter simple demographic and clinical variables
(i.e. age, gender, severity – top box) and discuss the relevance of the different side effects (there is a score 0 to 100 to select the best tolerability profile
according to personal preferences – left and right boxes). At the centre of the figure, results are presented as bar graphs reporting the
percentage allocated to each side effect and the ranking of the treatments, with the corresponding probability to be the best, the second best, etc. In
this working example, the patient is a female, aged between 51 and 65 years old, with moderate severity of symptoms, who is really concerned about
weight gain and sedation (the higher the score, the more important the adverse event to avoid). Legend: EPS, extra-pyramidal symptoms;
QTc, corrected QT interval
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the focus group recordings were then removed from the
digital voice recorder and transferred to a secure,
password protected storage facility in line with the
universities’ policies on data storage and protection.
Data were analysed thematically and managed using
the Framework method [11]. Transcripts were coded
and a working analytical framework was established.
Using the constant comparative method [12], any
similarities and differences in perspectives between
clinicians and patients/carers were established with
regard to the CDST. Transcript data were manually
inserted into a Framework matrix (Fig 2) to enable
ordering and data synthesis [11]. This enabled within
and across case analysis of the data from the three
focus groups identifying key themes relating to partic-
ipants’ views on the CDST and its application in the
clinical setting.
Results
The main themes that emerged related to CDST applica-
tions in clinical practice, communication, conflicting
priorities, record keeping and data management. Table 3
presents a summary of the main themes reported on.
Whilst in general, there was more congruence than
divergence in the perspectives of the consultant, primary
care and patient and carer focus groups, the views of the
groups were sometimes nuanced, based on their context-
ual needs, values, priorities and concerns. For example,
whilst all three groups viewed the CDST as a useful and
collaborative learning and decision-making tool, the
consultant group expressed concern that it should not
be viewed as a replacement for clinical judgement, whilst
a prominent concern of Primary Care participants was
that patients might become overloaded with worry if
provided with too much information. However, the
patients and carer group felt the amount of trust they
had in their doctor would be a key factor in the shared
decision making process. The study findings will now be
reported on in more detail.
Applications in clinical practice
Positive comments
All participants agreed that the CDST has the potential
for clinical applications in psychiatry. The majority
reported that it was a useful tool to support decision
making for prescribing. They felt the tool reminded
clinicians to consider all available treatment options (not
just the most effective, well known, or best tolerated).
They thought it prompted discussion between clinicians
and patients around potential side-effects, best evidence
and drug interactions: “I think it is a useful tool because
we’re not perfect so we will forget things and we will also
prescribe drugs with interactions that are going to be a
real problem.” (Consultant 12).
Most consultants viewed the CDST as an effective way
to standardise prescribing practices, by ranking interven-
tions according to their comparative efficacy and side-
effect profiles. This was seen as a more favourable method
Table 2 Topic guide used in focus group study
Questions
• Can you summarise what you think the clinical decision support
tool will be used for?
• Can you tell me what you think about the layout of the clinical
decision support tool?
• What are the strengths and weaknesses of using this tool in clinical
practice?
• Can you tell me what you like and don’t like about this clinical
decision support tool?
• Can you think of anything that could be added or removed from
the clinical decision making tool to improve it?
• How do you think patients and carers will respond to the clinical
decision support tool? Do you think it will impact on the
doctor-patient relationship? If so, how?
• Are there any patient groups for whom this tool may be particularly
useful or unhelpful?
• Are there any advantages or disadvantages of using this tool in
clinical practice?
• What do you think about the web-based interface?
• How do you feel using an electronic tool compares to using more
traditional methods in clinics?
Table 1 Characteristics of focus group participants
Participant demographics Psychiatrists (N = 12) General practitioners (N = 11) Patients and carers (N = 8) Total (N = 31)
Age (years) 30–45 4 7 1 12
> 45–60 7 4 2 13
> 60 1 0 5 6
Gender Male 6 3 5 13
Female 6 8 3 17
Ethnicity White (British) 7 9 8 24
White (Other) 5 1 0 6
Afro-Caribbean 0 1 0 1
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than relying on personally derived drug hierarchies, with
some consultants admitting that their prescribing prefer-
ences were not always based on the most up-to-date
evidence: “For me it almost seems like a formalisation or a
regularisation of what should be good practice anyway
with the information in there.” (Consultant 12).
The tool was perceived to be useful by clinicians
who had been practicing for a long time as well as
clinicians who were relatively new to practice. All cli-
nicians reported the CDST would be useful to help
remember and retain information about the severity
of different treatment side-effects across the different
interventions, especially when there is little difference
between certain drugs in terms of efficacy, boosting
their prescribing confidence as a result: “This is… a
way of quickly reminding us…which [drugs] are bet-
ter…I always hold in my head actually which one is
the best for [patients with] QTc prolongation … It
gives you an instant answer.” (Consultant 1).
Primary care participants suggested that the CDST
could inform prescribing practice by providing a history
of patients’ previous side-effects. They also felt that the
CDST provided a useful learning tool for clinicians if
they selected a lower ranking drug than the recom-
mended CDST treatment, by prompting them to ques-
tion their rationale for doing so: “You've asked the
patient what's important to them…It's come up with that
outcome based on that…It's a really useful learning tool
for us to be thinking about what our prescribing choices
are” (Primary Care 5).
Patients and carers described the CDST as ‘self-teach-
ing’, helping them make informed choices and allowing
them to readily access information than they previously
did not have: “It helps in making informed decisions
Fig. 2 Snapshot of the Framework Matrix used to undertake qualitative data analysis process
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because 20 years ago people weren’t being told about side
effects necessarily so they couldn’t even make important
choices.” (Patient and Carer 7).
Suggestions for change or improvement
Some consultants were wary of the CDST being used as
a replacement for clinical judgement and expressed con-
cern about “becoming blinkered by it”. They reported
the tool did not reflect the complex contextual clinical
assessment process, being unable to capture detailed
information about patient characteristics, time pressures,
anxiety, influence of carers, clinician experience and
organisational factors. Some clinicians said that this pro-
vided a significant limitation to the CDST’s usefulness:
“When we see someone… it changes completely the con-
text of the conversation…Depending on how much time
you have or depending on whether the person is having
an attack or not which I did not capture in this [tool].”
(Consultant 9).
However, other clinicians thought that the CDST
informed and enhanced clinical judgement, by providing
unbiased, credible, evidence-based information, thus
removing some of the reticence about prescribing drugs
that were not routinely used in practice: “Having this kind
of information…Would make you more likely to go and
look at the evidence for the drug that's being recommended
if it's one that you're not used to.” (Primary Care 9).
For patients and carers the CDST encouraged them to
consider different factors during the clinical assessment
process, rather than just focusing on one or two things:
“That’s what I like about the approach, it does assist
judgement, you’re not committing to anything, you’re
comparing bits.” (Patient and Carer 3).
All participants agreed that the CDST could be widely
used for other chronic conditions where medications
have to be tailored and adjusted over time such as other
psychiatric conditions (eg depression, diabetes, asthma
and hypertension).
Communication
Discussion of potential benefits and challenges
One major benefit of the CDST was perceived to be that
it opened up discussion about the possible side-effects of
medications. Some clinicians commented that the CDST
provided opportunity to fully discuss medications’
tolerability profile with patients, which they did not
otherwise always do. This was important, as clinicians
thought that the way they convey the severity of side-
effects to patients is likely to influence their subsequent
drug preferences: “How you explain some of these things
to patients [will]…very much influence what weight they
give to them.” (Consultant 8).
However, some primary care providers and patients/
carers highlighted that there are disadvantages to receiv-
ing too much information about possible medication
side-effects, as it might cause unnecessary worry and
result in clinicians spending considerable time reassuring
patients. Whilst it was important they were made aware
of the main side-effects from treatment, the majority of
patients and carers did not feel they needed to know
every detail, so long as their doctor was well informed.
This view was echoed by some consultants who reported
there was a danger of entering into a ‘minefield of
discussion’.
Most clinicians said that the CDST could help facilitate
the informed consent process, though a few thought it
Table 3 Summary of main themes emerging from the focus group dataset
Themes Applications in clinical
practice
Communication Conflicting priorities Record keeping and
data management
Key points raised • Clinical applications in
psychiatry and other
chronic conditions
• Supports standardized
decision making for
prescribing
• Reminder to consider
all treatment options
• Prompts discussion
between clinicians and
patients
• Boosts prescribing
confidence
• Useful learning tool
• Promotes informed
choice
• Enhances, but not
replacement for, clinical
judgment
• Does not reflect clinical
assessment process
• Promotes discussion about
medication side-effects
• May cause information
overload
• Facilitates informed consent
• Treatment choice of patient
and clinician may be at odds
• May optimise capacity, by
teasing out views
• Level of collaboration may vary
• Terminology too “medicalised”
• Improved presentation will
facilitate discussion
• Promotes collaboration but may
cause uncertainty in decision-making
• May increase compliance
• Patient’s healthcare priorities
need identifying to ensure
clinicians consider them
• Promotes personalised care;
but tool too disease-focused.
• Potential conflict if patients
feel they are being denied
recommended treatments; only
available medications should
be used in CDST
• Full range of CDST
recommendations could be
used to challenge clinical
commissioners
• Good record of consultation
• Potential to link CDST to
patient records
• Continually updated
evidence-base
• Outcomes presented are
understandable
• Concerns about data
reliability
• Easy to use
• Time saving: hard to use
within 10 min consultation,
but pays off long term
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might cause problems for patients with limited intellec-
tual capacity, creating tensions if their preferred treat-
ment choice was at odds with their clinician’s. However,
generally it was felt that the CDST could optimise
capacity, by teasing out patients’ views and preferences,
though the degree of clinician/patient collaboration
might vary: “Even somebody who’s quite psychotic might
have a fairly good idea of what side effect profile they
might prefer.” (Consultant 5).
Suggestions for change
Participants from all the three groups universally com-
mented that the terminology and language presented on
the CDST were too “medicalised”, making it difficult for
lay people to understand and potentially lead to ethical
issues around consent to treatment, as patients. There
was consensus that simpler language was required and
that clinicians needed a pre-determined knowledge of
the demographic and level of understanding of patients,
to avoid having to provide a ‘series of tutorials’ to explain
every acronym: “What concerns me is that it’s very easy
for a clinician to lead you at that point if you don’t really
understand what it is you’re looking at.” (Patient and
Carer 4).
Each group made recommendations for improving the
way the information was presented (including relabelling
and resizing scales, adding pictorial representations of
side-effects or increasing interactivity). This would facili-
tate discussions with patients and raise their awareness
of different side-effect profiles: “The interface needs to be
simplified and have lay terms and more explanation…To
facilitate the conversation a bit more.” (Primary Care2).
Showing the CDST’s screen to patients during a consult-
ation was a matter of discussion. Many patients said that
it could be distressing, causing confusion and uncertainty
during the decision-making process. However, some
patients and carers felt the CDST should be patient-facing
to promote collaboration in decision-making, so long as
this did not impinge on their clinician’s duty of care: “The
information must be there because if we’re to be transpar-
ent and it’s to be a co-production…To build trust and so
forth. The patient should have access to the same informa-
tion provided it doesn’t override the doctor’s duty of care to
that patient.” (Patient and Carer 8).
A couple of carers thought that having access to the
CDST interface might lead to some patients manipulat-
ing the tool until they received their preferred drug of
choice. However, primary care practitioners reported
that patients would require a lot of knowledge for this to
happen: “It would take quite a lot of knowledge to know
which ones to move…It up the top.” (Primary Care 11).
One patient commented that some clinicians may not
respond well to patients having an increased level of
control over the decision-making process, whilst others
felt that trust in the clinician-patient relationship was
vital for ensuring successful decision-making, something
the CDST could not control for: “A doctor is not going to
respond…well to somebody having done this and then
say, actually, what I need is…”. (Patient and Carer 1).
Primary care practitioners commented that the CDST
could increase patient compliance if it was tailored to
their needs: “If you’re helping people to tailor the things
that they prefer to avoid, I would hope that that would
improve compliance.” (Primary Care 9).
Conflicting priorities
Clinicians, patients and carers reported that prior to using
the CDST patients should be encouraged to declare a
checklist of their healthcare priorities, to assist with shared
decision-making, ensuring mismatched priorities are
identified and that their needs, views and perspectives are
listened to. This was viewed as a valuable way of ensuring
clinicians did not purely rely on their past prescribing
preferences: “What the patients come up with…They’ve
said what they do or don’t want…Use that as a guide of
what we should be thinking of using.” (Primary Care 5).
Many clinicians, patients and carers agreed that the
CDST promoted personalised care. However, they recog-
nised that the CDST was at times too disease-focused
and could not compensate for the lifestyle and human
factors that influence decision-making. The possibility of
incorporating other data into the CDST such as genes
and demographics was raised, to increase the CDST’s
accuracy: “What would make [the tool] potent is if you
could start to include more biological data about
patients.” (Consultant 4).
Other conflicting priorities were highlighted by primary
care practitioners who suggested that increasing pressures
on prescribing budgets meant the CDST should only iden-
tify medications available from within their own clinical
commissioning groups. They commented that conflict
could arise if patients felt they were being denied access to
recommended CDST treatments which were not commis-
sioned in their local area: “The cost effectiveness and the
limited choice is very important…If something flashes up,
potentially it can lead to some problems later down in the
relationship that they're not getting the best thing.”
(Primary Care 2).
However, from an educational perspective, it was
thought helpful to have access to the full range of CDST
recommendations, regardless of whether they were avail-
able from their clinical commissioning group. This could
allow the commissioners to be challenged about why
certain medications were not made available, as well as
facilitating data collection to compare local prescribing
practices against CDST recommendations: “From the
education point of view, then more information about
more drugs is fine. Because you can go away and talk to
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your clinical commissioning group about why this one
isn't available.” (Primary Care 9).
Record keeping and data management
According to the majority of clinicians, patients and
carers, the CDST could provide a good record of the con-
sultation. However, suggested improvements included
linking the CDST to patient clinical records’ database so
that individuals’ medication histories could be incorpo-
rated. Participants praised the CDST’s ability to continu-
ally update its evidence-base, build on existing best
available literature and present these outcomes in a quan-
titative and understandable way. However, some consul-
tants expressed concern about the reliability of data from
the network meta-analysis, commenting on the lack of
external validity of randomised controlled trials: “It’s a
highly selected group of patients ….” (Consultant 4).
Finally, most participants thought that the CDST was
easy to use, encouraging clinicians to use it on a daily
basis. The CDST was commended for focusing on one
specific aspect of the clinical consultation, saving time
by collating relevant drug information within one data-
base: “This particular tool serves a specific purpose…It’s
about deciding on how to treat them pharmaceutical-
ly….I think it’s fantastic.” (Patient and Carer 6).
A few primary care practitioners said that it could be
hard to use the CDST within a 10 min consultation
period, however they argued that this initial time invest-
ment would pay off long term: “If it comes to enabling
people to make a better choice, that's quite a major time
saving rather than having them coming back saying, oh I
didn't like it.” (Primary Care 11).
Discussion
The findings from this study provide useful insights into
the perspectives of clinicians, patients and carers with
regard to the usefulness of clinical support tools. They
have led the research team to consider how the CDST
might be optimised in the clinical setting to enable it to
be mutually beneficial to clinicians and patients. The
majority of participants felt the CDST could play a role
in regulating and standardising prescribing processes in
routine mental health practice.
Previous research has shown that computer assisted
guidance on drug prescribing can improve patients’
therapeutic outcomes, reduce costs and result in more
effective care outcomes [13]. This is something that par-
ticipants found the CDST valuable for, allowing them to
base their decision-making on verifiable, up-to-date evi-
dence and challenging their own assumptions about best
prescribing practice. The CDST has the potential to
build on good prescribing practice by weighting the clin-
ical effectiveness of drugs against the severity of side-
effects. This will enable clinicians, in conjunction with
patients, to make appropriate medication choices at an
individual level. Although some participants commented
that the CDST was too medicalised, this referred at large
to the terminology and language used. The CDST’s
concept, although based in biomedicine, engages with a
holistic approach to care and is embedded in the princi-
ples of personalised medicine and informed choice. This
concept of informed choice is critical in a society where
patients increasingly seek engagement in their healthcare
choices, to ensure that they have a better understanding
of the nature of their illness, against the backdrop of an
increasingly complex and fragmented healthcare system
[14, 15]. The CDST can help enable patients to make the
right healthcare decisions for themselves within the con-
text of their own lives, even if this maybe at odds with
the views and perspectives of clinicians [14].
As the findings highlighted, the CDST is not intended
to be a replacement for clinical judgement. The complex-
ities surrounding the clinical assessment, management
and treatment of mental health patients is multi-factorial.
It depends on human, environmental, cultural, social,
practical, physical and psychological factors and will not
always fit neatly within the medical model of care or the
CDST parameters. Although some clinicians expressed
concern that the CDST may blinker doctors and stop
them from considering other factors, we argue against
this. Just as clinicians rely on summaries about patients’
social circumstances, comorbidities and test results to
help build a comprehensive history, this background infor-
mation does not inhibit them from listening and respond-
ing to the immediate needs of patients. Similarly, having
access to evidence-based medication recommendations
should not inhibit clinicians from employing their own
clinical judgement. Rather, these recommendations form
one piece of a complex jigsaw that requires knowledge,
experience and expertise to complete [16].
The findings revealed that clinicians, patients and
carers placed value in the CDST’s ability to facilitate
discussion about the side-effect profiles of different psy-
chiatric drugs. A study carried out to ascertain whether
patients knew their diagnoses, treatment plans and
common side effects of prescribed medications, found
that less than half were able to list their diagnoses,
medication names and purpose, or associated medica-
tion side-effects [17]. This suggests an apparent lack
of communication between clinicians and patients.
The CDST can help rectify this, by pinpointing areas
for discussion that clinicians might otherwise omit
and by drawing specific side-effects to the attention
of patients. The time saving elements of the CDST
may also facilitate improved communication pathways
between patients and clinicians, by focusing on
priority areas for discussion. However, care must be
taken to consider the level of information desired by
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individual patients to avoid causing distress, confusion
or pressure in decision-making.
The issue of informed consent and capacity is integral
to decision-making in mental health. Research has shown
that deficits in understanding among individuals with psy-
chiatric illness or cognitive impairment can be improved
with educational interventions, especially when they are
presented in an organised and simplified manner [18].
Furthermore, multimedia resources which are interactive,
incorporate visual aids, are simple to use and have a clear
focus, have been shown to help align information to
individual needs and promote active engagement from
participants [19]. This highlights the need for modifi-
cations to be made to the CDST, to ensure that the
language and design features are easy to understand
and engage with, especially for mental health patients
who may have limited capacity. In addition, medica-
tions appearing on the CDSTs interface could be
stratified to ensure they align with those available
within specific healthcare localities.
The main limitation of this study is that patients vary
substantially in how much they wish to contribute to the
decision-making process [20]. Whilst some of them with
little input may be content with this, trusting their
clinician to make a treatment decision using the best
available evidence, other patients may view this as pater-
nalistic, remiss and lacking in understanding of what
their personal health priorities might be. Collaborative
decision-making between clinicians and patients can
empower patients, with positive impacts on their subse-
quent health outcomes [14, 15, 21]. The CDST has been
designed to have a shared interface between clinicians
and patients, however the level of collaboration is
subjective and dependent on the level of trust and reci-
procity within the clinician-patient relationship. Good
clinical judgement, an awareness of contextual factors
and good communication skills must be employed by
clinicians to succinctly assess the level of collaboration
required on an individual basis, support shared and
collaborative decision making and hence therapeutic
relationships and good clinical outcome [22].
Finally, the CDST was generally considered to be an
efficient, time-saving clinical tool and this is important
given escalating pressures on healthcare resources mak-
ing clinicians and patients aware of the brevity on their
consultations [23]. To this respect, it is worth noting
that research suggests that the quality, rather than the
length, of the consultation has the biggest impact on
patients’ satisfaction [24]. The CDST can support clini-
cians to navigate patient treatment and management
plans, whilst providing assurances that they are utilising a
robust and up to date evidence base, with regards to pre-
scribing practices. The study findings will guide future
development and evaluation of the CDST to ensure that
any modifications made reflect the preferences, needs and
priorities of clinicians and patients. Further testing of the
algorithm based CDST is planned to ensure that the
evidence used to inform it is both credible and reliable.
Recommendations
The CDST in the mental health and primary care settings
can be a useful clinical decision support, with recognised
value in promoting clinician-patient collaboration and
contributing to the development of personalised medicine.
The CDST can improve communication pathways be-
tween patients and clinicians, identifying care priorities
and providing an up-to-date platform for implementing
evidence-based practice. To further this aim, work is
planned with PPI/E representatives to ensure that the
medical terminology on the CDST is simplified to make it
accessible to lay populations. Whilst the CDST has been
designed to focus on prescribing practices within a mental
health context, other evidence-based algorithms could be
designed to incorporate factors such as demographic vari-
ations and non-pharmacological interventions, as well as a
variety of mental and physical health disorders. Primary
care practitioners may value the CDST for managing and
treating patients with long term conditions such as
hypertension and diabetes, within short clinic time
slots. Primary care practitioners require a broader range
of knowledge than practitioners in more specialised
secondary and tertiary care services. The CDST may be
particularly valuable in these circumstances, by providing
up-to-date, evidence based information on a variety of
health conditions in a timely manner, something that is
essential given the time-limited consultations available.
Conclusions
As well as providing a tool to support evidence-based
practice, we plan to use the CDST to gather feedback from
patients to increase its precision, by effectively incorporat-
ing everyday clinical information from ‘real-world’ individ-
uals with the best available evidence that is contained
within the CDST. This has the potential not only to
improve treatment outcomes, but also to strengthen the
evidence base around the interaction of specific drugs with
other pharmacological and psychosocial interventions,
whilst accounting for individual characteristics and patient
preferences.
Future research will also involve a pilot randomised
controlled trial to test the CDST. If shown to be
implementable in routine clinical practice in different
settings, the CDST could lead to changes in prescrib-
ing practices of clinicians, protecting patient safety,
whilst paving the way for precision medicine in
every-day mental health care.
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